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Abstract Introduction: In absence of randomized evidence to support safety of
conservative surgery (BCT) in locally advanced breast cancer (LABC), we analyzed
a cohort of 664 women with LABC treated during January 1998 to December 2002 at
Tata Memorial Hospital, Mumbai, India.
Materials and methods: All were treated with a multimodality regimen comprising
of neoadjuvant chemotherapy (NACT) followed by surgery (modified radical mas-
tectomy or BCT) and adjuvant radiotherapy and hormone therapy. The outcome
was evaluated to assess safety of BCT.
Results: 71% (469/664) women responded to NACT (22% clinical CR and 49% PR) and
28.3% (188/664) underwent BCT. Positive lumpectomy margins were reported in
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Breast conservation treatment in women with breast cancer 1078.5%, with gross presence of tumor at the margins in 2.3% requiring a revision sur-
gery. At a median follow-up of 30 months, local relapse rate was 8% after BCT and
10.7% after mastectomy. The 3-year local DFS was better post-conservation than
after mastectomy (87% vs 78%, P ¼ 0.02). The disease-free survival (DFS) was also
superior after BCT, 72% vs 52% (P < 0.001) at 3 years and 62% vs 37% (P < 0.001)
at 5 years respectively. On multivariate analysis, presence of lymphatic vascular
emboli (LVE) was the major significant predictor of local recurrence (P < 0.001,
HR 2.52, 95% CI 1.52e4.18). DFS was better after BCT [(P < 0.001, HR 2.0 (95% CI
1.38e2.91)]; shorter DFS was noted in LVE positive (HR 1.54, P ¼ 0.007) and larger
residual disease after NACT (HR 1.13, P ¼ 0.001).
Conclusion: BCT is technically feasible and safe post neo-adjuvant chemotherapy in
women with LABC with no detriment in outcome.
ª 2006 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
In spite of increasing awareness, locally advanced
breast cancer (LABC) still remains an important
problem in developing countries accounting for
nearly 30% of all breast cancer cases at presenta-
tion. Virtually all evidence regarding management
of these patients has been derived from results of
phase II studies or from retrospective reviews of
single institution experiences. It is well known that
women with LABC carry an increased risk of local
recurrence after primary treatment and have
a poorer overall survival, as compared to early
breast cancer.
Multimodality treatment has now become the
established approach to patient management in
locally advanced breast cancer.1 Neoadjuvant
chemotherapy in conjunction with surgery and
radiation therapy2,3 is the treatment of choice
for patients with locally advanced breast cancer.
Neoadjuvant chemotherapy downstages tumors
effectively, making breast conservation accept-
able.4,5 Another advantage of neoadjuvant therapy
is the in vivo assessment of tumor sensitivity to
chemotherapy, which allows optimization of avail-
able therapeutic agents. One disadvantage of neo-
adjuvant chemotherapy is that preoperative
treatment causes an alteration of prognostic infor-
mation regarding lymph node status prior to
systemic treatment. But it has been shown that
improved pathological response at the primary
site and axillary nodes correlates directly with
improved outcome.6e8 Although the optimal che-
motherapy regimen has not been established,
doxorubicin-containing regimens are considered
superior to non-doxorubicin-containing regimens
and have been the standard of care in many
centers.9 Currently, early results of neoadjuvant
trials with taxanes (NSABP B27, Aberdeen Trial)have shown better response rates compared to
anthracyclines.10 Presently at our institute, neo-
adjuvant anthracycline-based chemotherapy for
women with LABC has been the standard protocol
since 1998 with taxanes being used only in selec-
tive cases.
Breast conservation surgery followed by radio-
therapy is established as a safe and standard
treatment in early breast cancer. But can we
extrapolate these results and offer selected pa-
tients with locally advanced breast cancer (LABC)
breast conservation after down staging with che-
motherapy without compromising their final out-
come? In other words, how safe is conservative
surgery in these patients?
Safety of BCT in early breast cancer has been
proven in large randomized trials. No such
randomized clinical trial has been published in
LABC. An EORTC randomized trial carried out
previously in 410 women with LABC had concluded
that a multimodality treatment including CT and
HT had the greatest therapeutic benefit but did
not address the issue of surgical intervention.11 A
number of observational studies in locally
advanced breast cancer cases are available in litera-
ture but the sample sizes are either small,12e17 or
have included a mixed prognosis group comprising
of patients with stages I to III of breast cancer who
have received neoadjuvant chemotherapy.13
Presently a large randomized trial is being
conducted by EORTC in patients with locally
advanced breast cancer and results are still
awaited. In absence of such level I evidence,
we have critically looked retrospectively at a cohort
of patients with locally advanced T3eT4 disease to
evaluate the safety of breast conservation therapy
in this subset having a known poorer prognosis,
with the ultimate aim to achieve a better quality
of life without compromising on disease control.
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We analyzed 664 women with locally advanced
breast cancer who presented at the Breast Clinic
at our institute during January 1998 to December
2002. The median follow up in these women was
30 months (range 3e72 months). The clinical diag-
nosis of locally advanced diseasewas based on pres-
ence of any of the following features of locally
advanced disease: skin involvement (peau d’orange,
ulceration, skin infiltration, satellite nodules),
matted or fixed axillary lymph nodes, ipsilateral
supraclavicular or internal mammary lymph nodes,
fixity to chest wall, arm oedema, and no evidence
of distantmetastasis. All patients underwent an ini-
tial incision biopsy for tissue diagnosis, receptor
study and quadrant localization. A mammography
was performed for a baseline documentation of tu-
mour size and for a later comparison following che-
motherapy for response assessment and feasibility
for breast conservation. Metastatic work up was
mandatory to confirm absence of distantmetastasis
and included chest radiography, ultrasound/CT
scan of abdomen, liver function test, bone scan,
and relevant skeletal survey.
All patients underwent a standard multi modal-
ity treatment protocol comprising of neo-adjuvant
chemotherapy (2e6 cycles) till maximum clinical
response was achieved. This was followed by
surgery, completion of remaining chemotherapy
(if any) and sequential RT (chest wall & SCF). The
standard chemotherapy schedule consisted of a
total of 6-cycles of 3-weekly dose of Cyclophos-
phamide 500 mg/m2, Anthracycline (Adriamycin
50 mg/m2 or Epirubicin 90 mg/m2), and 5-Fluoro-
uracil 500 mg/m2. Tamoxifen 20 mg/day was
added after chemotherapy if the tumor was ER
and or PR positive.
Clinical response was documented using the
UICC criteria based on primary tumor response
and defined as follows: complete response (CR)
defined as complete clinical disappearance of
palpable tumor at primary site, partial response
(PR) (>50% reduction in primary tumor size), static
disease (SD) (<50% reduction or up to 25% increase
in tumor size), progressive disease (PD) (>25%
increase in primary tumor size).
Based on clinical response, 3e4 weeks after the
last chemotherapy, the patients either underwent
a breast conservation surgery (wide excision of
residual tumor along with a surrounding gross
1e1.5 cm margin of normal tissue in all cases
accompanied by a complete axillary clearance)
or, a modified radical mastectomy if found unsuitable
for or unwilling for BCT. No attempt was made toexcise the preoperative volume of disease during
conservation surgery. All the gross positive
margins, and focal positive margins, in presence
of extensive intraductal component (EIC), were
subjected to margin revision to attain a free path-
ological margin prior to the starting of adjuvant
radiotherapy treatment.
Pathological response was stated as complete if
no tumor was found at primary site or in the
axillary nodes. Postoperative sequential radiother-
apy was administered (with a Linear Accelerator
with bi-tangential portals) to the breast or chest
wall to a maximum dose of 50 Gy in 25 fractionated
doses over 5 weeks. A tumor bed boost of 15e
20 Gy was administered after BCT. Supraclavicular
radiation was given to a dose of 50 Gy in 25 frac-
tions to supraclavicular fossa (SCF) in all patients.
In case of pathological positive supraclavicular
nodes an additional boost of 10 Gy is administered
to SCF.
After completing the primary treatment, all
patients were followed up at 6 monthly intervals
for 5 years and annually thereafter. Mammography
was performed annually after BCT on all patients.
Disease free survival (DFS) was defined as the
interval between date of surgery, and the date of
first recurrence. Survival curves were calculated
using the KaplaneMeier method and compared by
Log rank test. Cox regression was used to evaluate
possible predictors in the time to event outcomes
of loco regional DFS. All statistical analysis was
carried out using SPSS 11.5 statistical package
program.
Results
Between January 1998 and December 2002, 664
patients with locally advanced breast cancer un-
derwent treatment at the Breast Clinic. Age of
patients ranged from 22 to 81 years (mean age
47.6 years), with 54% women in the pre and peri-
menopausal age group. The mean tumor size at
presentation was 7.4 cm (range 3e20 cm). At pre-
sentation, 82.8% had T4 tumors and T1e3 tumors
in 17.2%. Supraclavicular lymph node was found
at presentation in 15%; locally advanced signs
such as peau d’orange in 36%, ulceration or skin in-
filtration in 26%, satellite nodules in 1% and more
than one sign of locally advanced status in
22% cases. The tumor was positive for estrogen
receptors in 24.7% and progesterone receptors in
31.5% cases; 37% were ER and or PgR positive.
The median follow up was for 30 months (range
3e72 months) (Table 1).
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Factors N All BCT MRM
Mean age (in years) 664 47.6 (22e81) 45 46
Mean clinical t size (cm) 642 7.4 (3e20) 6 8.3
Mean pathological t size (cm) 539 3.5 1.5 4.1
No. (%) No. (%) No. (%)
Menopausal status 664
Pre & Perimenopausal 359 (54.1) 83 (44.1) 222 (46.6)
Postmenopausal 305 (45.9) 105 (55.9) 254 (53.4)
ER Positive 664 164 (24.7) 43 (22.9) 121 (25.4)
PR Positive 664 209 (31.5) 63 (33.5) 146 (30.7)
EIC Positive 608 68 (11.6) 8 (4.8) 60 (13.6)
LVI Positive 608 185 (27.9) 37 (21.6) 148 (33.9)
T stage
T1e3 664 114 (17.2) 56 (30.9) 56 (11.8)
T4 550 (82.8) 130 (69.1) 420 (88.2)
Post NACT LN status
N ve 658 214 (32.5) 88 (47.1) 126 (26.8)
N þ ve 444 (67.5) 99 (52.9) 345 (73.2)
Post NACT LN status
N 0 658 214 (32.5) 88 (47.1) 126 (26.8)
1e3 197 (30.0) 55 (29.6) 142 (30.6)
4e10 177 (26.9) 31 (16.7) 129 (27.8)
>10 70 (10.6) 13 (7) 74 (15.5)
NACT responders (CR þ PR) 664 467 (70.3%) 165 (92.7%) 302 (67.1%)
NACT non-responders (SD þ PD) 161 (24.3%) 13 (7.3%) 148 (32.9%)
Not noted 36 (5.4%)Neoadjuvant anthracycline-based chemother-
apy was completed in 93.2% patients; 4.8% re-
ceived CMF and 2% received taxanes. A clinically
complete response was documented in 21.7% and
partial response in 48.6% (responders 70.3%); static
or progressive disease was registered in 24.3%.
Response to neo-adjuvant chemotherapy was not
documented in 5.4% cases. A pathological CR, on
the other hand, was seen in only 8% of all cases.
Post chemotherapy, 32% patients were LN negative
and nearly an equal proportion (30%) had 1e3 LN
positive for residual metastasis; 4e10 positive LN
in 27%, and >10 positive LN in 10.6%.
Surgical intervention and histopathological
features
The mean clinical tumor size was 7.4 cm (range 3e
20 cm) at presentation, and post neo-adjuvant che-
motherapy the pathological tumor size was reduced
to 3.5 cm resulting in a breast conservation rate of
28.3%. The mean tumor size in women who had
breast conservation was 1.5 cm as compared to
4.1 cm in those who had a mastectomy. A total of
188 (28.3%) women underwent conservation sur-
gery and the remaining 476 (71.7%) underwentmastectomy. Following conservative surgery,
a gross positive margin was reported in 2.3% cases
and focal positive margin in 6.5%. The margin was
negative in the remaining 91.2% cases. Multicentric-
ity in the form of extensive intraductal carcinoma
(EIC) was detected in 11.6% (65/664) and lympho-
vascular emboli were seen in 27.9% (185/664) cases.
Follow up and survival analysis
Follow up data was available in 664 patients.
Median follow up was for 30 months (range 3e72)
for surviving patients, with a relatively longer me-
dian follow up of 32 months in breast conservation
group as against 25 months in mastectomy group.
In total, there was evidence of recurrent disease
in 186 out of 664 patients (28%) with local recur-
rences in 66 patients (9.9%). The 3-year and
5-year disease free survival for the entire cohort
was 54% and 38% respectively (Fig. 1).
The respective 3 and 5-year disease-free sur-
vival was 72% and 62% for the conservation group.
In the mastectomy group, the 3 and 5-year dis-
ease-free survival was significantly lower, being
52% and 37% respectively (P < 0.001) (Fig. 2). The
local disease-free survival at 3 years was better
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P ¼ 0.02) (Fig. 3).
Fifteen cases (8%) developed LR (IBTR) following
breast conservation as compared to 51 patients
(10.7%) who developed chest wall recurrence after
mastectomy (P ¼ 0.02, log rank 5.38). Distant
recurrences were also fewer in conservation group
with 11.1% patients presenting with distant
recurrence as compared to 25.6% patients after
mastectomy (P < 0.0001, log rank 22.44) (Table 2).
Predictors of local recurrence
When correlated with prior treatment and post-
chemotherapy histopathological features, pres-
ence of LVE (P < 0.001), more extensive surgery
Figure 1 Disease-free Survival in all patients with lo-
cally advanced breast cancer treated at Tata Memorial
Hospital from 1998e2002 (N ¼ 664).
Figure 2 KaplaneMeier Analysis plot of Disease-free
survival comparison between conservation group
(n ¼ 188) and mastectomy group (n ¼ 476).(mastectomy with axillary clearance) (P ¼ 0.02),
and hormone insensitive tumor (P < 0.05) were
associated with a higher local recurrence rates in
a univariate analysis. In Cox regression multivariate
model, however, the presence of LVE (P < 0.001,
HR 2.52, 95% CI 1.52e4.18) correlated significantly
with a higher risk for local recurrence. A higher
local relapse rate was also observed after mastec-
tomy [P ¼ 0.031, HR 1.98, (95% CI 1.06e3.69)]; an
important observation was that the risk of local
failure increased with increasing post NACT resid-
ual tumor size (P < 0.001, HR 1.22, 95% CI 1.09e
1.36). However, menopausal status, type of che-
motherapy, receptor status, degree of pathologi-
cal response to NACT, post chemotherapy nodal
disease and presence of EIC did not predict in-
creased risk for local relapse (Tables 3 and 6).
Predictors of any recurrence
Independently as well as on multivariate analysis,
type of surgery performed was the strongest pre-
dictor of any recurrence (P < 0.001, HR 2.00,
CI ¼ 1.38e2.91) favoring breast conservation treat-
ment; followed by presence of LVE (P ¼ 0.007, HR
1.54, CI ¼ 1.12e2.12). Increasing size of residual
Figure 3 KaplaneMeier Analysis plot of Local Disease-
free survival comparison between conservation group
(n ¼ 188) and mastectomy group (n ¼ 476).
Table 2 Recurrence pattern
Recurrences BCT
N ¼ 188
patients
Mastectomy
N ¼ 476
patients
Total
N ¼ 664
patients
Local 15 (8.0%) 51 (10.7%) 66 (9.9%)
Regional 10 (5.3%) 37 (7.7%) 47 (7.0%)
Distant 21 (11.1%) 122 (25.6%) 143 (21.5%)
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of disease recurrence (P ¼ 0.001, HR 1.13, 95%
CI 1.05e1.22). Premenopausal status, residual
disease in axillary nodes, and age less than 35 years
independently predicted a higher risk for relapse
but were not found to be significant on multivariate
analysis; clinical stage at presentation and hormone
responsiveness of primary tumor also did not corre-
late with a higher risk for relapse (Tables 4 and 6).
Predictors of distant recurrence
The most significant factor correlating with distant
metastasis was the type of surgery performed with
more recurrences reported in mastectomy group
(P < 0.0001, log rank 22.44). The other factors
independently correlating with higher risk for dis-
tant metastasis were larger tumor at presentation,
residual nodal disease after NACT, young age,
presence of LVE, premenopausal status, and ER
negative tumors (Table 5). On multivariate analysis
Table 3 Predictors of local recurrences in women
with LABC-Univariate analysis
Factors Log Rank P value
LVE (þve vs ve) 16.6 <0.001
Type of Surgery (MRM vs BCT) 5.38 0.02
ER status (ve vs þve) 4.04 0.04
PgR status (ve vs þve) 3.72 0.05
Age (<35 years vs >35 years) 3.31 0.07
Response to NACT
(Non-responder vs Responders)
3.19 0.07
Residual axillary
LN status (Nþ vs N0)
3.09 0.08
Pathological
response (RD vs CR)
0.92 0.34
EIC (ve vs þve) 1.65 0.20
Menopausal status (Pre vs Post) 1.49 0.22
Clinical T stage (T4 vs T1e3) 0.06 0.81
Table 4 Factors predicting any recurrence by uni-
variate analysis
Factors Log Rank P value
Type of Surgery
(MRM vs BCT)
17.76 <0.001
LVE (þve vs ve) 12.9 <0.001
Residual nodal axillary
status (Nþ vs N0)
9.44 0.002
Menopausal status
(Pre vs Post)
4.67 0.03
Age (<35 years vs >35 yrs) 5.37 0.02
PgR status (ve vs þve) 3.88 0.05
Clinical T stage (T4 vs T1e3) 2.69 0.10
Pathological response (RD vs CR) 1.98 0.16
ER status (ve vs þve) 1.99 0.16
EIC (þve vs ve) 0.06 0.81of factors influencing distant recurrences, mastec-
tomy group had higher risk (HR 3.04, CI 1.59e
5.85), followed by presence of LVE (HR 1.57, CI
1.05e2.35). A larger residual tumor at the primary
site, a younger age, and ER negative tumors also
correlated with poorer prognosis (Table 6).
Discussion
Safety of breast conservation therapy in early
stage breast cancers is well supported by large
Table 5 Factors predicting distant recurrence by
univariate analysis
Factors Log rank P value
Type of Surgery
(MRM vs BCT)
22.44 <0.0001
Clinical T stage
(T4 vs T1e3)
7.46 0.006
Residual nodal
axillary status
(Nþ vs N0)
6.10 0.01
Age (<35 years vs
>35 years)
5.17 0.023
LVE (þve vs ve) 5.40 0.02
Menopausal status
(Pre vs Post)
5.09 0.02
ER status (ve vs þve) 4.51 0.03
Pathological
response (RD vs CR)
1.60 0.20
PgR status (ve vs þve) 1.60 0.19
Table 6 Significant predictors of recurrence by Cox
regression analysis
Factors P value HR (95% CI)
Local recurrence
LVE (þve vs ve) <0.001 2.52 (1.52e4.18)
Pathological t size <0.001 1.22 (1.09e1.36)
Type of Surgery
(MRM vs BCT)
0.03 1.98 (1.06e3.69)
Any recurrence
Type of Surgery
(MRM vs BCT)
<0.001 2.00 (1.38e2.91)
Pathological t size 0.001 1.13 (1.05e1.22)
LVE (þve vs ve) 0.007 1.54 (1.13e2.12)
Distant recurrence
Type of Surgery
(MRM vs BCT)
0.01 3.04 (1.59e5.85)
LVE (þve vs ve) 0.03 1.57 (1.05e2.35)
Pathological t size 0.03 1.10 (1.01e1.20)
Estrogen receptor
(ve vs þve)
0.04 1.71 (1.01e2.90)
Age (<35 years vs
>35 years)
0.048 1.70 (1.00e2.86)
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mastectomy with breast conservation surgery and
radiation therapy for T1e2 tumors. Larger tumors
were excluded in these trials from a conservative
approach to surgery fearing poor local control and
cosmesis. No adequately powered randomized
control trial is available in LABC to address the
issue of safety of BCT in these patients. Most of
available evidence is from observational cohort
studies. An EORTC randomized trial carried out
previously in 410 women with LABC had concluded
that a multimodality treatment including CT and
HT had the greatest therapeutic benefit but did
not address the issue of surgical intervention.11
The most clearly established advantage of NACT
is in its ability to allow more BCT (22e45%) to be
performed in patients who were initially ineligi-
ble.12e14 The cohort of patients of LABC included
in this series had a mean clinical tumor size of
7.4 cm (range 3e20 cm), treated by a multimo-
dality approach and examined for the feasibility
and safety of breast conservation surgery. We
could achieve breast conservation in 28.3% women
post neoadjuvant chemotherapy.
Women undergoing BCT had a superior 3-year
DFS as compared to after mastectomy (72% in BCT
vs 52% after mastectomy, P < 0.001) with a lower
LR (8%). Similar outcomes have been reported in
other studies of locally advanced tumors post
NACT.15,16 Reports in literature of studies evaluat-
ing local recurrence after NACT and BCT have
shown conflicting results. While some single insti-
tution studies have reported a low local recurrence
rate of 2e10%, others have reported a much higher
incidence up to 16e28%.12,13,18,19 It is worth noting
that some of the studies that reported higher rates
of local recurrences after NACT included large
percentages of patients for whom radiation
therapy was the only loco regional treatment ad-
ministered,12,20 without an attempt to resect the
primary tumor site and some studies even included
patients with inflammatory carcinomas as well.
A large percentage of patients who attain a clini-
cal CR have residual disease detected at surgical
resection. In our series, also although we had
a complete clinical response of 22.9%, a pathologi-
cal complete response was documented in only
8.0%. Therefore surgery remains an important
component of BCT for all patients treated with
NACT.
At the same time, a few series that included
patients who were treated both with surgery and
radiation have also reported higher LR rates. For
example, in the Institute Bergonie series, 28%
experienced a LR.2 Differences in surgical ap-
proaches may also have contributed to thedifference in outcomes. In addition to grade, size
of tumor, LVI and EIC, local recurrence may be re-
lated to residual disease within the breast, which
may be assessed by examining the excision margin.
Therefore, a careful pathological assessment after
surgery is essential to ensure free resection mar-
gins.21 Eleven percent of the patients from the
Institute Curie series18 had positive margins (and
reported a LR of 27%) as against our gross margin
positive rate of 2.3%. In our institute, all patients
with gross positive margins were managed under
a standard protocol ensuring negative margins
(by undergoing a re-excision or treated with an
additional radiotherapy boost).
Conservative surgery was found to be associated
with a lower local recurrences than following
mastectomy (HR 1.98, CI 1.06e3.69, P ¼ 0.03).
Similar findings were seen in the study reported
from North Carolina14 and some other studies.15
This probably does not really represent a true
impact of extent of surgery, rather the inherent
selection bias that discriminates between women
who were responders (hence, offered breast con-
servation) and those who were non-responders
(and therefore underwent mastectomy). The pro-
jected 3-year local disease free survival outcome
in our series was better post conservation (88%)
than after mastectomy (78%) confirming the safety
of BCT.
Subset analysis of induction chemotherapy trials
reveals a statistically significant improvement in
survival for patients found to have a complete
pathological response at the time of definitive
surgery.22 In our series, the degree of pathological
response to chemotherapy, particularly a complete
pathological response did not predict the likeli-
hood of developing a local recurrence (Table 3).
However, a significant relationship may be over-
looked here by virtue of the fact that there are
only a small number of patients who had a patho-
logical CR (8.0%) and thus it is possible that there
are not enough events within the subgroup to allow
a significant relationship to be shown.
The presence of residual nodal metastasis did
represent a risk factor for disease recurrence
especially distant recurrence. This observation is
in concordance with the observations made by
McIntosh,16 Buchholz19 and others,7 that nodal in-
volvement after primary chemotherapy retains its
significance and predicts an increased risk of de-
veloping recurrent disease. This finding is perhaps
unsurprising, as it has been clearly demonstrated
in patients who have treatments not involving
NACT, that axillary lymph node involvement is
itself an adverse prognostic factor. Residual axil-
lary nodal metastasis persisting after neo-adjuvant
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prognostic factor.
Larger clinical tumor size has been found to be
a statistically significant factor-influencing out-
come in some studies. Jacquilat et al.20 Ahern
et al. from West mead hospital,23 Australia and
Buchholz et al.19 found greater clinical T stage
and advanced disease at presentation to be associ-
ated with a greater risk of recurrence. Larger
tumor size at presentation did not correlate with
increased local relapses in our cohort of patients,
but did correspond to a higher risk for distant re-
lapse. However, post NACT, larger residual tumor
in the primary site correlated directly with an in-
creasing risk for disease recurrence locally (HR
1.22. CI 1.09e1.36, P < 0.001) as well as at distant
site (HR 1.10, CI 1.01e1.20, P ¼ 0.03).
Conclusion
Breast conservation can safely be offered to
women with locally advanced breast cancers who
respond to neo-adjuvant chemotherapy. Surgery
remains an essential part of treatment even in
good responders. Obtaining a clear surgical excision
margin is essential for reducing local recurrences
and should be consolidated with postoperative
radiotherapy. Prognosis is determined by post
NACT residual nodal disease, residual tumor in
the breast, and presence of LVI. Responders self-
select themselves out as a subgroup with better
clinical outcome. The current use of taxanes in the
neo-adjuvant setting promises a higher pathologi-
cal CR as compared to anthracyclines and may
possibly eventually translate into an overall better
outcome.
The identification of prognostic factors presents
an opportunity to investigate and identify markers
that may allow optimal prediction of response to
adjuvant radiation and chemotherapy or both, and
hopefully lead to future strategies for the im-
proved management of both locally advanced as
well as early breast cancers.
References
1. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD,
Paulus D, et al. Management of stage III primary breast
cancer with primary chemotherapy, surgery, and radiation
therapy. Cancer 1998;62:2507e16.
2. Mauriac L, MacGrogan G, Avril A, et al. Effects of primary
chemotherapy for operable breast cancer more than 3 cm;
a unicentre randomised trial with 124 month-median follow
up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann
Oncol 1999;10:47e52.3. Baillet F, Rozec C, Ucla L, Chauveinc L, Housset M, Weil M.
Treatment of locally advanced breast cancer without mas-
tectomy: 5- and 10-yr results of 135 tumors larger than 5
cm treated by external beam therapy, brachytherapy and
neoadjuvant chemotherapy. In Pisa Symposia in Oncology.
Breast Cancer from Biology to Therapy, 1992. p. 22
[abstract].
4. Vlastos G, Mirza NQ, Lenert JT, Hunt KK, Ames FC, Feig BW,
et al. The feasibility of minimally invasive surgery for stage
IIA, IIB, and IIIA breast carcinoma patients after tumor
downstaging with induction chemotherapy. Cancer 2000
Mar 15;88(6):1417e24.
5. El-Didi MH, Moneer MM, Khaled HM, Makarem S. Pathologi-
cal assessment of the response of locally advanced breast
cancer to neoadjuvant chemotherapy and its implications
for surgical management. Surg Today 2000;30(3):249e54.
6. Pierga JY, Mouret E, Dieras V, Laurence V, Beuzeboc P,
Dorval T, et al. Prognostic value of persistent node involve-
ment after neoadjuvant chemotherapy in patients with
operable breast cancer. Br J Cancer 2000 Dec;83(11):
1480e7.
7. Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM,
Ames FC, et al. Incidence and impact of documented
eradication of breast cancer axillary lymph node metastases
before surgery in patients treated with neoadjuvant chemo-
therapy. Ann Surg 1999 Jul;230(1):72e8.
8. Gajdos C, Tartter PI, Estabrook A, Gistrak Jaffer S,
Bleiweiss IJ. Relationship of clinical and pathological
response to neoadjuvant chemotherapy and outcome of
locally advanced breast cancer. J Surg Oncol 2002;80:
4e11.
9. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK,
Dhingra K, et al. Clinical course of breast cancer patients
with complete pathologic primary tumor and axillary lymph
node response to doxorubicin-based neoadjuvant chemo-
therapy. J Clin Oncol 1999 Feb;17(2):460e9.
10. Heys SD, Sarkar T, Hutcheon AW. Primary docetaxel chemo-
therapy in patients with breast cancer e Impact on re-
sponse and survival. Breast Cancer Res Treat 2005 March;
90(2):169e85.
11. Bartelink H, Rubens RD, van der Schueren E, Sylvester R.
Hormonal therapy prolongs survival in irradiated locally
advanced breast cancer: a European Organization for
Research and Treatment of Cancer Randomized Phase III
Trial. J Clin Oncol 1997;15:207e15.
12. Touboul E, Lefranc JP, Blondon J, Buffat L, Deniaud E,
Belkacemi Y, et al. Primary chemotherapy and preoperative
irradiation for patients with stage II larger than 3 cm or
locally advanced non-inflammatory breast cancer. Radio-
ther Oncol 1997;42:219e29.
13. Merajver SD, Weber BL, Cody R, Zhang D, Strawderman M,
Calzone KA, et al. Breast conservation and prolonged
chemotherapy for locally advanced breast cancer: the
University of Michigan experience. J Clin Oncol 1997;15:
2873e81.
14. Cance WG, Carey LA, Calvo BF, Sartor C, Sawyer L,
Moore DT, et al. Long-term outcome of neoadjuvant ther-
apy for locally advanced breast carcinoma: effective clini-
cal downstaging allows breast preservation and predicts
outstanding local control and survival. Ann Surg 2002;236:
295e303.
15. Clark J, Rosenman J, Cance W, Halle J, Graham M. Extend-
ing the indications for breast-conserving treatment to pa-
tients with locally advanced breast cancer. Int J Radiat
Oncol Biol Phys 1998;42:345e50.
16. McIntosh SA, Ogston KN, Payne S, Miller ID, Sarkar TK,
Hutcheon AW, et al. Local recurrence in patients with large
114 V. Parmar et al.and locally advanced breast cancer treated with primary
chemotherapy. Am J Surg 2003;185:525e31.
17. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD,
Oswald MJ, Outlaw ED, et al. Breast conservation after neo-
adjuvant chemotherapy: the MD Anderson cancer center
experience. JCO 2004;22:2303e12.
18. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR,
Durand JC, et al. Neoadjuvant versus adjuvant chemother-
apy in premenopausal patients with tumors considered
too large for breast conserving surgery: preliminary results
of a randomised trial: S6. Br J Surg 1996 Feb;83(2):
149e55.
19. Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J,
Salas J, et al. Predictors of local-regional recurrence after
neoadjuvant chemotherapy and mastectomy without radia-
tion. Eur J Cancer 1994;30A:645e52.20. Jacquillat C, Weil M, Baillet F, Borel C, Auclerc G, de
Maublanc MA, et al. Results of neoadjuvant chemotherapy
and radiation therapy in the breast-conserving treatment
of 250 patients with all stages of infiltrative breast cancer.
Am J Surg 1998 Dec;176(6):502e9.
21. Macmillan RD, Purushotham AD, George WD. Local recur-
rence after breast-conserving surgery for breast cancer.
Br J Surg 1996 Feb;83(2):149e55.
22. Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K,
Buchholz TA, et al. Residual metastatic axillary lymph
nodes following neoadjuvant chemotherapy predict disease-
free survival in patients with locally advanced breast cancer.
Cancer 1990;66:119e29.
23. Ahern V, Barraclough B, Bosch C, Langlands A, Boyages J.
Locally advanced breast cancer: defining an optimum treat-
ment regimen. Int J Radiat Oncol Biol Phys 1994;28:867.
